EUVIMEDEUVIMED entdecken
Crossref

Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Yueyue Yang, Hongli Liu, Haoxing Yuan, Kaikai Lyu, Haiyang Zhong iD, Yanlian Li, Danyan Cao, Wenchao Zhao, Haoran Zhang, Bing Xiong iD, Danqi Chen, Dong Guo iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yueyue Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Hauptthemen laut MEDLINE: Transcription Factors, Polycystic Kidney, Autosomal Dominant, Cell Cycle Proteins, Drug Design. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Outstanding Youth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic modulation plays a pivotal role in restraining tumor progression by governing gene expression and protein function. Autosomal dominant polycystic kidney disease (ADPKD), characterized by neoplastic-like progression, can be managed by inhibiting cyst expansion. Of note, the epigenetic regulator BRD4 has been implicated in ADPKD’s development. Our prior research unveiled a class of (pyrazol-3-yl) pyrimidin-4-amine compounds as potent BRD4 inhibitors with additional kinase inhibition, which might induce unwanted biological activities. To address this, this study focused on creating selective BRD4 inhibitors through structure-guided design, minimizing off-target kinase interactions. Specifically, compound 23 emerged as an efficacious and selective BRD4 inhibitor in cellular and embryonic kidney models of ADPKD, along with encouraging outcomes in murine models. Collectively, these results highlight the therapeutic potential of targeted BRD4 inhibition as a safe and efficacious strategy for managing ADPKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsPolycystic Kidney, Autosomal DominantCell Cycle ProteinsDrug DesignAnimalsHumansMiceStructure-Activity RelationshipNuclear ProteinsProtein Kinase InhibitorsBromodomain Containing Proteins

Substanzen

Transcription FactorsBRD4 protein, humanCell Cycle ProteinsNuclear ProteinsProtein Kinase InhibitorsBromodomain Containing Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, China.

ORCID-Profile: Haiyang Zhong, Bing Xiong, Dong Guo

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Outstanding Youth Fund

Zitieren

APA

Yang, Y., Liu, H., Yuan, H., Lyu, K., Zhong, H., Li, Y., Cao, D., Zhao, W., Zhang, H., Xiong, B., Chen, D., & Guo, D. (2025). Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02128

Vancouver

Yang Y, Liu H, Yuan H, Lyu K, Zhong H, Li Y, et al. Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02128

BibTeX
@article{Yang2025,
  author = {Yang, Yueyue and Liu, Hongli and Yuan, Haoxing and Lyu, Kaikai and Zhong, Haiyang and Li, Yanlian and Cao, Danyan and Zhao, Wenchao and Zhang, Haoran and Xiong, Bing and Chen, Danqi and Guo, Dong},
  title = {Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02128}
}
Kostenlos starten →